Abstract: Several embodiments relate to methods of repairing and/or regenerating damaged or diseased tissue comprising administering to the damaged or diseased tissues compositions comprising exosomes. In several embodiments, the exosomes comprise one or more microRNA that result in alterations in gene or protein expression, which in tum result in improved cell or tissue viability and/or function.

Abstract: Several embodiments relate to methods of repairing and/or regenerating damaged or diseased tissue comprising administering to the damaged or diseased tissues compositions comprising exosomes. In several embodiments, the exosomes comprise one or more microRNA that result in alterations in gene or protein expression, which in turn result in improved cell or tissue viability and/or function.

Abstract: A data processing method, a network interface card, an electronic device, and a storage medium. The method includes: determining a target dispatch queue to be dispatched from a host memory in response to a doorbell signal sent by a target host, where the doorbell signal indicates that there is a target message to be sent; determining a current target dispatch state of the target dispatch queue, where the target dispatch state is obtained based on an activity and a credit value corresponding to the target work queue element; determining whether a dispatch mechanism corresponding to the target dispatch queue is valid based on the target dispatch state, where the dispatch mechanism indicates whether the target dispatch queue is allowed to be dispatched; and performing a dispatch operation on the target work queue element and the target message in response to the dispatch mechanism being valid.

Abstract: The present disclosure provides compositions and methods related to the delivery of therapeutic medicines to the heart for treating a cardiac injury, such as those that occur due to a myocardial infarction (MI). In particular, the present disclosure provides novel hydrogel-based compositions that safely and effectively deliver a therapeutic agent to the pericardial cavity of the heart to treat the cardiac injury.

Abstract: The present disclosure provides compositions and methods related to engineered extracellular vesicles (EVs). In particular, the present disclosure provides a novel delivery platform for administering therapeutic agents to a subject using engineered EVs. As provided herein, EVs can be used to deliver biologically active cargo (e.g., mRNA, tumor antigens, small molecule drugs) to a subject to treat and/or prevent disease (e.g., viral infection, cancer, etc.).

Abstract: The present disclosure relates to the preparation method of glufosinate or derivatives thereof.

Abstract: Provided is a method for preparing the L-glufosinate of formula (I) or a derivative thereof.

Abstract: Provided herein are methods and systems for performing an automated tagging of features in digital micrographs representing slides with tissue samples. Automated tagging of features may include automated entry of metadata associated with whole slide images or regions of the whole slide images.

Abstract: A preparation method for glufosinate or a salt, an enantiomer or a mixture of enantiomers in all ratios thereof, the method being especially suitable for the preparation of glufosinate, and greatly shortening steps in an existing preparation process. Especially in the preparation of L-glufosinate, the product can effectively retain the ee value of the raw materials.

Abstract: This invention relates generally to the discovery of novel mammalian lung spheroids and lung spheroid cells and uses thereof.

Abstract: Provided herein are methods and systems for performing an automated tagging of features in digital micrographs representing slides with tissue samples. Automated tagging of features may include automated entry of metadata associated with whole slide images or regions of the whole slide images.

Abstract: Disclosed are fibrin-specific nanogels. The fibrin-specific nanogels can comprise a fibrin binding moiety conjugated to a polymeric matrix (e.g., a crosslinked polyacrylamide matrix). By varying the morphology of fibrin-specific nanogels (e.g., by varying the crosslinker density and/or the three-dimensional structure of the fibrin-specific nanogels), fibrin-specific materials which mimic the biophysical characteristics of platelets can be formed. The resulting materials can be used in a variety of biomedical applications (e.g., for drug delivery, to promote wound healing, to treat thrombotic events, and to treat coagulative disorders).

Abstract: The present disclosure relates to the preparation method of glufosinate or derivatives thereof.

Abstract: Using lung tissues as a source, mammalian lung progenitor cells lung spheroids and lung spheroid cells (LSCs) were prepared. In one embodiment mammalian LSCs were prepared by (i) culturing mammalian lung tissue explant cells under adherent culture conditions to form a first lung cell outgrowth culture; (ii) culturing the first lung cell outgrowth culture under low-adherence conditions to form lung spheroids; and (iii) culturing the lung spheroids under adherent culture conditions so as to form LSCs. The low-adherence conditions may be a cell culture or suspension. The lung spheroids or LSCs may be formulated into pharmaceutical compositions. Uses such as treatment of lung diseases or diagnostics are also provided. Lung spheroids and LSCs represents a simple and highly reproducible method to generate therapeutic lung cells.

Abstract: The present disclosure provides compositions and methods relating to the use of stents treated with therapeutic biologics for the treatment of cardiovascular diseases and conditions. In particular, the present disclosure provides novel compositions and methods for conjugating therapeutic extracellular vesicles to a stent to not only regulate vascular remodeling and inflammation, but also promote the regeneration of the injured tissue.

Abstract: The present invention relates to a method for preparing glufosinate or an analogue and an intermediate thereof. The method comprises: a) reacting a compound of formula (II), an alcohol of formula (III) and a compound of formula (V); and b) hydrolyzing the product of the reaction above to obtain glufosinate of formula (IV) or an analogue thereof.

Abstract: Provided herein are methods and systems for performing an automated tagging of features in digital micrographs representing slides with tissue samples. Automated tagging of features may include automated entry of metadata associated with whole slide images or regions of the whole slide images.

Abstract: The present invention relates to a method for preparing glufosinate or analogues thereof.

Abstract: Provided are a method for preparing L-glufosinate and the intermediate compounds of formula (V) and formula (III).

Abstract: Provided herein are methods and systems for performing an automated quality control analysis of digital micrographs representing slides with tissue samples. An automated quality control analysis may comprise analyzing digital micrographs of histology slides for gross errors and excessive regions of blurriness.